Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NBIX 
Neurocrine Biosciences Inc (NBIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NBIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $160.19
1 Year Target Price $160.19
| 15 | Strong Buy |
| 7 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.55% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.44B USD | Price to earnings Ratio 42.61 | 1Y Target Price 160.19 |
Price to earnings Ratio 42.61 | 1Y Target Price 160.19 | ||
Volume (30-day avg) 25 | Beta 0.24 | 52 Weeks Range 84.23 - 157.98 | Updated Date 06/30/2025 |
52 Weeks Range 84.23 - 157.98 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.68% | Operating Margin (TTM) 4.14% |
Management Effectiveness
Return on Assets (TTM) 8.75% | Return on Equity (TTM) 12.43% |
Valuation
Trailing PE 42.61 | Forward PE 24.33 | Enterprise Value 11915798315 | Price to Sales(TTM) 5.16 |
Enterprise Value 11915798315 | Price to Sales(TTM) 5.16 | ||
Enterprise Value to Revenue 4.94 | Enterprise Value to EBITDA 21.3 | Shares Outstanding 98965800 | Shares Floating 97783178 |
Shares Outstanding 98965800 | Shares Floating 97783178 | ||
Percent Insiders 1.09 | Percent Institutions 99.3 |
Analyst Ratings
Rating 5 | Target Price 160.19 | Buy 7 | Strong Buy 15 |
Buy 7 | Strong Buy 15 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neurocrine Biosciences Inc
Company Overview
History and Background
Neurocrine Biosciences, Inc. was founded in 1992. It is a biopharmaceutical company focused on neurological, endocrine and psychiatric disorders. The company has evolved from research-focused to a commercial organization with a portfolio of approved products.
Core Business Areas
- Neurology: Focuses on developing and commercializing therapies for neurological disorders, including tardive dyskinesia, Parkinson's disease, and essential tremor.
- Endocrinology: Develops and commercializes therapies for endocrine-related disorders such as congenital adrenal hyperplasia.
- Psychiatry: Develops and commercializes therapies for psychiatric disorders, including women's health.
Leadership and Structure
The leadership team includes Kevin Gorman (CEO), Jude Onyia (Chief Medical Officer), and Matt Abernathy (Chief Commercial Officer). The company is structured with research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- INGREZZA (valbenazine): INGREZZA is approved for the treatment of tardive dyskinesia. As of 2023, INGREZZA holds significant market share for tardive dyskinesia treatments, estimated to be around 80%. Competitors include Teva Pharmaceutical Industries (Austedo).
- ORILISSA (elagolix): ORILISSA is approved for the management of endometriosis-associated pain. AbbVie is a partner for ORILISSA. While specific market share fluctuates, ORILISSA is a significant player in endometriosis treatment. Competitors include AbbVie's Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; and norethindrone acetate tablets) and generics of GnRH agonists.
- CRINEOS (hydrocortisone): CRINEOS is the first FDA-approved therapy for congenital adrenal hyperplasia (CAH). It is anticipated to have a significant market share in the CAH treatment space. There are not many competitors, it is largely based on steroid use and alternatives.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and significant competition. The market is driven by unmet medical needs and the aging population. There is an increasing number of biotech companies focusing on niche markets with unmet needs and increasing regulatory scrutiny. The demand for prescription drugs is also increasing.
Positioning
Neurocrine Biosciences is positioned as a specialized biopharmaceutical company focused on neurological, endocrine, and psychiatric disorders. Its competitive advantage lies in its focus on targeted therapies and its established commercial infrastructure for INGREZZA.
Total Addressable Market (TAM)
The total addressable market for Neurocrine's current and pipeline products is estimated to be in the billions of dollars. The TAM for tardive dyskinesia is substantial, with a significant unmet need. The company's strategic focus places it well to capture a substantial portion of this TAM. It is expected to exceed $3 billion.
Upturn SWOT Analysis
Strengths
- Strong commercial infrastructure for INGREZZA
- Focus on specialized therapeutic areas
- Innovative pipeline of product candidates
- Established partnerships with other pharmaceutical companies
- Experienced leadership team
Weaknesses
- Reliance on a limited number of key products
- High dependence on the success of clinical trials
- Potential for generic competition
- Limited diversification across therapeutic areas
- Market volatility can cause potential swings in revenue
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or products
- Geographic expansion into international markets
- Development of new formulations for existing products
- Increasing awareness of tardive dyskinesia and other target disorders
Threats
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Pricing pressures from payers
- Patent expirations
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- TEVA
- ABBV
- VRAY
Competitive Landscape
Neurocrine Biosciences faces competition from established pharmaceutical companies such as Teva and AbbVie. Its competitive advantage lies in its specialized focus on neurological and endocrine disorders, its strong commercial infrastructure for INGREZZA, and its innovative pipeline.
Major Acquisitions
Idorsia Pharmaceuticals U.S., Inc.
- Year: 2024
- Acquisition Price (USD millions): 53
- Strategic Rationale: Enhance focus on core therapeutic areas, acquiring a compound with focus on epilepsy.
Syneos Health
- Year: 2024
- Acquisition Price (USD millions): 14
- Strategic Rationale: Acquiring a Phase 2 clinical program of a novel investigational muscarinic receptor agonist from Syneos Health
Growth Trajectory and Initiatives
Historical Growth: Neurocrine Biosciences has experienced significant growth in recent years, driven by the commercial success of INGREZZA and ORILISSA.
Future Projections: Analysts project continued revenue growth for Neurocrine Biosciences, driven by INGREZZA and the potential launch of new products. However, clinical trial outcomes and regulatory approvals are key factors influencing future performance.
Recent Initiatives: Recent initiatives include advancing its pipeline of product candidates, expanding its commercial infrastructure, and pursuing strategic collaborations and acquisitions.
Summary
Neurocrine Biosciences is a strong biopharmaceutical company with a focus on neurological, endocrine, and psychiatric disorders. INGREZZA's success is driving revenue growth, but reliance on a limited number of key products remains a concern. Successful pipeline development and strategic acquisitions will be key to sustained growth. Competitor actions and clinical trial outcomes remain risks the company needs to monitor closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Neurocrine Biosciences Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. The data provided may not be real-time and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurocrine Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1996-05-23 | CEO & Director Mr. Kyle W. Gano Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.neurocrine.com |
Full time employees 1800 | Website https://www.neurocrine.com | ||
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.